In humans, LPLAT2 mutations cause type 1 congenital generalized lipodystrophy (CGL, also called Berardinelli–Seip lipodystrophy), a rare disorder that includes a total lack of subcutaneous body fat from birth, increased appetite, accelerated growth, and other metabolic complications including severe insulin resistance, hypertriglyceridemia, hepatic steatosis, and early onset diabetes (75). Here, AGPAT2 is linked to fatty liver disease.